United Therapeutics Corp

United Therapeutics Corp maintains a strong liquidity position with $1.56 billion in cash and equivalents and no long-term debt, resulting in a debt-to-equity ratio of 0.0 and a current ratio of 6.6. The company's liquidity is further supported by a free cash flow of $894.3 million, which provides flexibility for strategic investments or shareholder returns. Profitability metrics indicate robust performance, with a return on equity (ROE) of 18.81% and a return on assets (ROA) of 16.94%, both exceeding the industry median for pharmaceutical firms. The company's operating margin of 46.9% (calculated from operating income of $1.49 billion on revenue of $3.18 billion) reflects efficient cost management and pricing power in its core markets. Geographically, United Therapeutics derives the majority of its revenue from the United States, with a concentration risk score of high due to over 90% of revenue coming from a single country. Segment-wise, the company operates in a single business segment focused on pulmonary hypertension and organ transplant therapies, with no material diversification across product lines. The company's growth trajectory is supported by a strong revenue base of $3.18 billion and a positive outlook for the current fiscal year. Analysts project a mean price target of $639.96, suggesting a potential upside of 13% from the current market price of $565.87. The company's capital expenditure of -$526 million indicates a reduction in investment, which may reflect a shift toward optimizing existing assets rather than expansion. Risk factors for United Therapeutics include regulatory scrutiny in the pharmaceutical sector and potential pricing pressures from payers and government programs. However, the company's low dilution risk and absence of immediate liquidity concerns reduce near-term shareholder dilution pressures. No dilution sources were identified in recent filings or disclosures. Recent events include strong earnings performance and positive analyst sentiment, with 12 of 16 analysts issuing "buy" or "strong buy" ratings. The company's financial health and market position remain stable, with no material adverse events reported in the latest filings.